Results filed 3 November 2026 · Market cap ₹1,777 crore · PE 19.8
GrowthGuidance maintainedTranscript read
Revenue
+58.2%
on a year ago
EBITDA
+87.7%
on a year ago
Profit to shareholders
+96.3%
on a year ago
EBITDA margin
12.2%
+0.8 pts on last quarter
Shree Pushkar Chemicals delivered strong Q2 FY27 revenue growth of 58.2% YoY to INR 403.5 crores, driven by favorable pricing in dye intermediates following Chinese supply disruptions and Kharif fertilizer volumes. However, quality of earnings was poor as operating cash flow turned negative to -INR 53.35 crores in H1 FY27 due to an 85% jump in trade receivables and inventory movements, funded by doubling short-term debt to INR 210.6 crores. Management maintained FY27 revenue guidance of INR 1,250–1,300 crores with triple-digit net profit, but exhibited low disclosure transparency regarding a newly approved INR 70 crore capex and gross margin contraction.
Source: Shree Pushkar Chemicals & Fertilisers Limited’s filing to NSE, 2 November 2026. Operating profit is revenue less every expense except interest, so it leaves out other income and exceptional items. n.m.: not meaningful, because the earlier figure was zero or negative, or the latest one is a loss.
What stood out
Significant divergence between reported profits and operating cash flows due to severe working capital dragSourceOperating cash flow turned negative at -INR 53.35 cr in H1 FY27 compared to +INR 32.90 cr in H1 FY26, driven by a working capital outflow of INR 136.75 cr (Presentation, slide 11).
Sharp surge in trade receivables and short-term debt over the six-month periodSourceTrade receivables expanded by 85.3% from INR 179.2 cr as of March 2026 to INR 332.1 cr as of September 2026, while current borrowings doubled from INR 103.6 cr to INR 210.6 cr (Presentation, slide 10).
Management explicitly refuses to disclose product chemistry and business details for approved INR 70 cr capexSourcePunit Makharia stated: 'Sir, I will not discuss the product. I am sorry. What we are going to produce? What is the product? What is the chemistry of the product? What is the market potential of the product? What is the name of the product? I will not like to discuss on this, sir.' (Concall transcript, original page 10).
Guidance
Metric
Guidance
Period
Consolidated RevenueSource'...we should be able to achieve at least INR1,250 crores of total sales... visibility of INR1,250 to INR1,300 crores will be able to be achieved without the production of Unit 6.' (Punit Makharia, Transcript, original pages 6, 10).
At least INR 1,250 to 1,300 crores
FY27
Consolidated Profit After TaxSource'...profitability should be in three digits. This is my visibility.' (Punit Makharia, Transcript, original page 6).
Three digits (> INR 100 crores)
FY27
Consolidated RevenueSource'...if I talk about next year, like 2027-2028, in my opinion, we should be somewhere closer to near around INR2,000 crores... In your books 2,000, hold 1,800' (Punit Makharia, Transcript, original pages 14, 16).
INR 1,800 to 2,000 crores
FY28
Tailwinds
Sharp surge in chemical segment realization due to Chinese environmental compliance shutdownsSource'In China, there is a huge shortage going on in terms of dye intermediates, mainly because of various compliances in terms of environment and safety norms in China.' (Punit Makharia, Transcript, original page 6).
Strong Kharif seasonal volume support for fertilizer operationsSource'Secondly, this was the Kharif season peak in this particular quarter, so mainly because of this, the company has been able to build a better volume.' (Punit Makharia, Transcript, original page 6).
Operationalization of captive renewable energySource'10 megawatt DC solar project at Nanded, Maharashtra commenced operations during this quarter... total installed solar capacity on a consolidated basis has increased to 20.6 megawatt' (Punit Makharia, Transcript, original page 4).
Headwinds
Gross margin compression despite higher selling pricesSourceConsolidated gross profit margin declined by 320 bps YoY to 30.0% in Q2 FY27 from 33.2% in Q2 FY26 due to higher raw material costs and inventory adjustments (Presentation, slide 9; Deepak Beriwala, Transcript, original page 12).
Anticipated seasonal weakness in Q3 fertilizer demand aggravated by poor rainsSource'...definitely there is a situation of poor rains and drought issues in Maharashtra and certain parts of Madhya Pradesh... in quarter three, mainly because of a poor season in terms of fertilizers, it may remain a bit subdued.' (Punit Makharia, Transcript, original pages 6, 8).
Subdued sulfuric acid plant operations due to high input sulfur pricesSource'It was a question that sulfur was at a very high price, and whereas sulfuric acid, because of the high price, the sulfuric acid was not able to sell... So, we have run our plant on lower levels.' (Punit Makharia, Transcript, original page 13).
Uncertainty surrounding government fertilizer subsidy declarationsSource'...right now the subsidy has not even been declared by the central government, which is again expected to be on 5th of this month, though it should have been done by the end of September.' (Punit Makharia, Transcript, original page 9).
New businesses and products
capacity expansion · Commercial production commenced in August 2026 (Q2 FY27)
Unit 5 Dye Manufacturing Expansion
Expected benefit
Addition of 6,000 MTPA dye capacity to support growing customer demand
Risks
Global demand remains weak; management noted cautious optimism on incremental volume uptake
Timeline
Commenced August 2026
Investment
INR 37 crores (incurred)
SourceCommercial production at Unit 5 commenced during Q2 FY27 adding 6,000 MTPA capacity (Transcript, original page 4; Presentation, slide 16).
new product · Board approved; planning stage
Unit 5 New Chemical Plant
Expected benefit
Potential top line of approximately INR 250 crores at 75% utilization on 3,000 MTPA capacity
Risks
Undisclosed product details and technology risks
Timeline
Expected commissioning by March 2028
Investment
INR 70 crores planned (funded via internal accruals and INR 45 cr promoter warrant issue)
SourceBoard approved capex of INR 70 cr for 3,000 MTPA plant by March 2028; funding includes INR 45 cr warrant issue to promoter (Transcript, original pages 4, 10; Presentation, slide 16).
capacity expansion · Plant ready, importing raw materials for trial production starting end November/December 2026
Unit 6 Complex Fertilisers & Acid Expansion at Ratnagiri
Approval delays (PDIL inspection, NBS policy inclusion for subsidy eligibility)
Timeline
Trials post-Diwali (Nov/Dec 2026); commercial ramp up in FY28
Investment
INR 85 crores planned (INR 78 crores incurred)
SourceUnit 6 trials expected post-Diwali, commercial sales contribution expected in FY28 (Transcript, original pages 7, 11; Presentation, slide 16).
capacity expansion · Under execution
Unit 8 Complex Fertilisers Expansion at Meghnagar (Madhya Bharat Phosphates)
Expected benefit
Adding 3,00,000 MTPA of complex fertilisers capacity
Risks
Regulatory approvals and execution delays
Timeline
Target completion March 2028
Investment
INR 350 crores planned (INR 93 crores incurred as of Sep 2026)
SourceUnit 8 Meghnagar expansion adding 3,00,000 MTPA targeted for March 2028 (Presentation, slide 16).
other · Commissioned in August 2026 (Q2 FY27)
10 MW DC Solar Power Plant at Nanded, Maharashtra
Expected benefit
Reduces grid dependence and operating energy costs under Open Access scheme
Timeline
Commenced August 2026
Investment
INR 35 crores (fully incurred)
SourceSolar Plant 2 (10 MW DC) commenced in August 2026, taking total consolidated solar capacity to 20.6 MW DC (Transcript, original page 4; Presentation, slide 16).
Things to check
Extreme negative operating cash flow of -INR 53.35 cr in H1 FY27 despite INR 58.6 cr reported PATSourceCash Flow statement shows Cash Flow from Operating Activities turned negative to -INR 53.35 cr compared to +INR 32.90 cr in H1 FY26 due to working capital absorption of INR 136.75 cr (Presentation, slide 11).
Trade receivables spiked by 85.3% in six months, accompanied by doubling of short-term borrowingsSourceTrade receivables rose to INR 332.1 cr from INR 179.2 cr, while current borrowings increased from INR 103.6 cr to INR 210.6 cr between March 2026 and September 2026 (Presentation, slide 10).
Refusal to disclose project details for major capex partially funded via preferential promoter warrantsSourceCMD declined to state the product chemistry or details for the INR 70 cr plant while the board approved issuing INR 45 cr in warrants to the promoter for the project (Transcript, original pages 4, 10).
Withdrawal of subsidiary merger after prolonged NCLT delaySourceManagement confirmed withdrawing the NCLT merger application of Kisan Phosphates and Madhya Bharat Phosphates due to prolonged legal delays (Transcript, original page 14).
How the call went
Management exhibited low transparency on crucial capital allocation and operational questions. The CMD outright refused to disclose the product profile of a new INR 70 crore capex on the call, deflected gross margin inquiries offline, and gave erratic, informal forward revenue figures that he subsequently walked back on the same call.
Specific or vague
Low to moderate; management shared top-line targets but refused product disclosures, margin explanations, and exact quantum of opportunistic gains.
Candour
Mixed; management was upfront that H-Acid/dye price surges are temporary and unsustainable, but deflected questions regarding product lines and gross margins.
The hard questions
Poorly handled; questions regarding why gross margins fell, why Unit 5's new capex is twice as expensive per ton, and receivable buildups were dismissed or directed offline.
What analysts pressed on
Substantial increase in trade receivables and working capital strain
Decline in gross margin despite higher realizations and chemical price spikes
Sustainability of elevated H-Acid pricing and opportunistic earnings
Reasoning behind the higher capex per unit of capacity for the new Unit 5 plant
Impact of poor rainfall and El Nino on fertilizer volumes in H2 FY27
Answers that sidestepped
Refusal to disclose the new product, chemistry, or market potential for the INR 70 cr Unit 5 capex, telling the analyst to visit the office privately (Transcript, original page 10).
Deflecting the explanation for gross margin compression by asking the analyst to talk to the CFO offline (Transcript, original page 12).
Refusing to quantify the exact contribution of opportunistic H-Acid pricing to Q2 revenue and profits, claiming complexity due to integration (Transcript, original pages 13-14).
Numbers against the story
Management emphasized strong revenue growth (+58.2% YoY) and EBITDA growth (+87.7% YoY) driven by realization and volume gains. However, the reported numbers reveal underlying weaknesses not highlighted in the narrative: gross margins contracted by 320 bps YoY, trade receivables expanded by 85% in six months to INR 332.1 cr, and operating cash flows fell deeply into negative territory (-INR 53.35 cr in H1 FY27), necessitating a doubling of short-term debt to INR 210.6 cr.
Figures: the company’s results filing with NSE, linked under the table.
Notes written by gemini-3.8-flash from the documents above on 15 November 2026. They summarise what the company said and can contain mistakes: check the source passage before relying on a point. Not investment advice.